Improved adherence with contingency management

AIDS Patient Care and STDs

Volumn 21, Issue 1, 2007, Pages 30-39

  Rosen, Marc I ^a,b   Dieckhaus, Kevin ^c   McMahon, Thomas J ^a,d   Valdes, Barbara ^c   Petry, Nancy M ^c   Cramer, Joyce ^a,b   Rounsaville, Bruce ^a,b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

^c UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

^d Yale University School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CANNABIS; COCAINE; ILLICIT DRUG; OPIATE DERIVATIVE;

ARTICLE; CONTINGENT VALUATION; DRUG ABUSE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PATIENT COUNSELING; PILL; PRESCRIPTION; TOXICITY TESTING; TREATMENT OUTCOME; VIRUS LOAD;

ADULT; ANTI-HIV AGENTS; COUNSELING; FEMALE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; MOTIVATION; PATIENT COMPLIANCE; SUBSTANCE ABUSE, INTRAVENOUS; TREATMENT REFUSAL; VIRAL LOAD;

EID: 33846817324     PISSN: 10872914     EISSN: None     Source Type: Journal    
DOI: 10.1089/apc.2006.0028     Document Type: Article

References (35)

1. Baker R. 3-drug therapy reduces deaths and new AIDS-related illnesses by 50%. Beta Bulletin of Experimental Treatments for Aids: a Publication of the San Francisco AIDS Foundation, 1997.
2. Palella FJ, Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998;338:853-860.
3. Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med 2000;133:21-30.
4. Bozzette SA, Joyce G, McCaffrey DF, et al. Expenditures for the care of HIV-infected patients in the era of highly active antiretroviral therapy [see comment]. N Engl J Med 2001;344:817-823.
5. Schackman BR, Goldie SJ, Weinstein MC, Losina E, Zhang H, Freedberg KA. Cost-effectiveness of earlier initiation of antiretroviral therapy for uninsured HIV-infected adults. Am J Public Health 2001;91:1456-1463.
6. Ammassari A, Antinori A, Cozzi-Lepri A, et al. Relationship between HAART adherence and adipose tissue alterations. J Acquir Immune Defic Syndr Hum Retrovirol 2002;31(Suppl 3):S140-S144.
7. Bouhnik AD, Chesney M, Carrieri P, et al. Nonadherence among HIV-infected injecting drug users: The impact of social instability. J Acquir Immune Defic Syndr Hum Retrovirol 2002;31(Suppl 3):S149-S153.
8. Ickovics JR, Meade CS. Adherence to antiretroviral therapy among patients with HIV: A critical link between behavioral and biomedical sciences. J Acquir Immune Defic Syndr Hum Retrovirol 2002;31(Suppl 3):S98-S102.
9. HIV/AIDS Treatment Adherence, Health Outcomes and Cost Study Group. The HIV/AIDS Treatment Adherence, Health Outcomes and Cost Study: Conceptual foundations and overview. AIDS Care 2004;16(Suppl 1):S6-S21.
10. Perno CF, Ceccherini-Silberstein F, De Luca A, et al. Virologic correlates of adherence to antiretroviral medications and therapeutic failure. J Acquir Immune Defic Syndr Hum Retrovirol 2002;31(Suppl 3):S118-S122.
11. Haynes RB, Yao X, Degani A, Kripalani S, Garg A, McDonald HP. Interventions to enhance medication adherence. Cochrane Database Syst Rev 2005;(4):CD000011.
12. Simoni JM, Pantalone DW, Frick PA, Turner BJ. Enhancing antiretroviral adherence: A review of published reports of RCTs and on-going NIH-funded research. In: Management IfD, ed. Best Practices in the Behavioral Management of Chronic Disease. Vol. II. Los Altos; 2005.
13. Simoni JM, Frick PA, Pantalone DW, Turner BJ. Antiretroviral adherence interventions: A review of current literature and ongoing studies. Top HIV Med 2003;11:185-198.
14. Carroll KM, Sinha R, Nich C, Babuscio T, Rounsaville BJ. Contingency management to enhance naltrexone treatment of opioid dependence: A randomized clinical trial of reinforcement magnitude. Exp Clin Psychopharmacol 2002;10:54-63.
15. Chick J, Gough K, Falkowski W, et al. Disulfiram treatment of alcoholism. Br J Psychiatry 1992;161:84-89.
16. Chaisson RE, Barnes GL, Hackman J, et al. A randomized, controlled trial of interventions to improve adherence to isoniazid therapy to prevent tuberculosis in injection drug users [see comment] Am J Med 2001;110:610-615.
17. Rigsby MO, Rosen MI, Beauvais JE, et al. Cue-dose training with monetary reinforcement - Pilot study of an antiretroviral adherence intervention. J Gen Intern Med 2000;15:841-847.
18. Sorensen JL, Haug N., Delucchi K., Gruber V, Tulsky J, Hall SM. Voucher reinforcement trial to improve methadone treatment for injection drug users with HIV infection. Paper presented at: College on the Problems of Drug Dependence, San Juan, Puerto Rico, 2004.
19. Cramer JA, Rosenheck R. Enhancing medication compliance for people with serious mental illness. J Nerv Ment Dis 1999;187:53-55.
20. Rosen MI, Rigsby MO, Salahi JT, Ryan CE, Cramer JA. Electronic monitoring and counseling to improve medication adherence. Behav Res Ther 2004;42:409-422.
21. Stout RL, Wirtz PW, Carbonari JP, Del Boca FK. Ensuring balanced distribution of prognostic factors in treatment outcome research. J Stud Alcohol Suppl 1994;12:70-75.
22. Teng EL, Chui HC. The Modified Mini-Mental State (3MS) examination. J Clin Psychiatry 1987;48:314-318.
23. Rosen MI, Ryan C, Rigsby M. Motivational enhancement and MEMS review to improve medication adherence. Behav Change 2002;19:183-190.
24. Petry NM, Tedford J, Austin M, Nich C, Carroll KM, Rounsaville BJ. Prize reinforcement contingency management for treating cocaine users: How low can we go, and with whom? Addiction 2004;99:349-360.
25. McLellan AT, Kushner H, Metzger D, et al. The Fifth Edition of the Addiction Severity Index. J Subst Abuse Treat. 1992;9:199-213.
26. Reitan RM, Wolfson D. The Halstead-Reitan Neurological Test Battery: Theory and Clinical Interpretation. Tuscon, AZ: Neuropsychology Press; 1985.
27. Beck AT, Steer, R.A., Brown, G.K. Beck Depression Inventory - Second Edition manual. San Antonio, TX: The Psychological Corporation; 1996.
28. Chesney MA, Ickovics JR, Chambers DB, et al. Self-reported adherence to antiretroviral medications among participants in HIV clinical trials: the AACTG Adherence Instruments. AIDS Care 2000;12:255-266.
29. Walsh JC, Mandalia S, Gazzard BG. Responses to a 1 month self-report on adherence to antiretroviral therapy are consistent with electronic data and virological treatment outcome. AIDS 2002;16:269-277.
30. Frahm N, Korber BT, Adams CM, et al. Consistent cytotoxic-T-lymphocyte targeting of immunodominant regions in human immunodeficiency virus across multiple ethnicities. J Virol 2004;78:2187-2200.
31. Festinger DS, Marlowe DB, Croft JR, et al. Do research payments precipitate drug use or coerce participation? Drug Alcohol Depend 2005;78:275-281.
32. Rosen MI, McMahon TJ, Lin H, Rosenheck RA. Effect of social security payments on substance abuse in a homeless mentally ill cohort. Health Serv Res 2006;41:173-191.
33. Yeni PG, Hammer SM, Carpenter CCJ, et al. Antiretroviral treatment for adult HIV infection in 2002 - Updated recommendations of the international AIDS Society-USA panel. JAMA 2002;288:222-235.
34. Bangsberg DR, Charlebois ED, Grant RM, et al. High levels of adherence do not prevent accumulation of HIV drug resistance mutations. AIDS 2003;17:1925-1932.
35. Rounsaville BJ, Rosen MI, Carroll KM. Contingency management to enhance medication compliance in addicts. In: Higgins ST, Silverman K, Heil SH, eds. Contingency Management in the Treatment of Substance Use Disorders: A Science-Based Treatment Innovation. New York, NY: The Guilford Press; (in press).